Iomai Reports 'Going Concern' Qualification in 10-K

Saturday, March 29, 2008 General News J E 4
GAITHERSBURG, Md., March 28 Iomai Corporation(Nasdaq: IOMI) today announced, in compliance with NASDAQ marketplace rules,that the independent audit report included in the Company's Annual Report onForm 10-K filed with the Securities and Exchange Commission on March 27, 2008for the fiscal year ended December 31, 2007 contained a "going concern"qualification. This disclosure is required under NASDAQ marketplace rules anddoes not represent any change to the Company's Annual Report on Form 10-K forthe year ended December 31, 2007 and filed on March 27, 2008 with the SEC.


Iomai Corporation discovers and develops vaccines and immune systemstimulants, delivered via a novel, needle-free technology calledtranscutaneous immunization (TCI). TCI, discovered by researchers at theWalter Reed Army Institute of Research, taps into the unique benefits of amajor group of antigen-presenting cells found in the outer layers of the skin(Langerhans cells) to generate an enhanced immune response. Iomai isleveraging TCI to enhance the efficacy of existing vaccines, develop newvaccines that are viable only through transcutaneous administration and expandthe global vaccine market. Iomai currently has four product candidates indevelopment: three targeting influenza and pandemic flu and one to preventtravelers' diarrhea. For more information on Iomai, please visit

SOURCE Iomai Corporation


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
CureHIV Reaches Out to Bill and Melinda Gates to F...
Leading Epilepsy Advocates Propose Strategies to H...